GlassScriptPhysician profile
Jie Chen
NPI 1336410398
$21,561.80
in general payments reported to CMS, 2019-2025
30 companies · $6,175 in 2025
The $6,175 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,556 · 2022: $2,080 · 2023: $5,903 · 2024: $5,849 · 2025: $6,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $1,800 · Education: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,514.82 |
| Consulting Fee | $1,800.00 |
| Education | $611.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,561.83 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $2,000.01 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $1,991.09 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $1,954.29 | 2021-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $1,898.86 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $1,618.78 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $1,259.95 | 2022-2025 | Sotyktu |
| Ucb, INC. | $1,160.43 | 2021-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $1,070.48 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $1,063.78 | 2022-2024 | Vtama |
| Lilly USA, LLC | $919.87 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $730.02 | 2021-2025 | |
| Galderma Laboratories, L.P. | $704.43 | 2021-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $558.96 | 2021-2025 | |
| Incyte Corporation | $480.57 | 2021-2025 | Opzelura |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $387.93 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $356.41 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $222.10 | 2021-2025 | Cabtreo, Arazlo, Jublia |
| Botanix Sb INC | $185.78 | 2025 | Sofdra |
| Organon LLC | $108.10 | 2025 | Vtama |
| Almirall LLC | $74.56 | 2021-2025 | Klisyri, Seysara |
| Journey Medical Corporation | $50.00 | 2023 | |
| Epi Health, LLC | $41.08 | 2021-2022 | |
| Leo Pharma INC. | $36.15 | 2022 | |
| Verrica Pharmaceuticals INC. | $27.31 | 2024 | Ycanth |
| Sandoz INC. | $24.15 | 2021 | |
| Mission Pharmacal Company | $23.61 | 2021 | |
| Vyne Pharmaceuticals INC. | $19.16 | 2021 | |
| Nabriva Therapeutics, Plc | $18.08 | 2022 | |
| Strata Skin Sciences, INC. | $14.03 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.